mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼治疗CNLC Ⅲ期肝细胞癌有效性和安全性的前瞻性研究

doi:10.3969/j.issn.1009-976X.2024.01.001

摘要/Abstract

摘要： 目的探索静脉mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼在CNLC Ⅲ期肝细胞癌中的有效性及安全性（NCT05412589）。方法本研究为单臂、开放、前瞻性临床研究,计划入组35例未经治疗的CNLC Ⅲ期肝细胞癌患者。主要研究终点为基于RECIST 1.1标准评估的客观缓解率（ORR）,次要研究终点包括：基于mRECIST标准评估的ORR,和基于RECIST 1.1标准和mRECIST标准评估的疾病控制率（DCR）、无进展生存时间（PFS）,以及总生存时间（OS）、手术转化率、治疗相关不良反应（TRAE）等。结果收集并分析2021年4月至2023年4月期间符合入排标准并签署同意书入组的26例肝细胞癌患者资料。中位随访时间为13个月,ORR为61.5%（RECIST v1.1）和73.1%（mRECIST）,临床缓解率为26.9%,病理完全缓解率为23.1%,DCR为96.2%,mPFS和mOS均尚未达到,均超过9个月。手术转化率为57.7%,均实现R0切除。TRAE≥3级不良事件发生率为50%。结论静脉mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼是治疗CNLC Ⅲ期肝细胞癌的一种有效、安全、易行的策略,初步研究效果类似于FOLFOX-HAIC联合靶免治疗。

关键词: 肝细胞癌, 门静脉主干癌栓, 全身化疗, 免疫检查点抑制剂, 抗血管生成靶向药物

Abstract: Objective The combination of anti-angiogenesis and immune checkpoint blockade showed promising outcomes for advanced HCC. Hepatic artery infusion chemotherapy （HAIC） combined with apatinib and camrelizumab could augment treatment efficacy in preliminary study. But HAIC had disadvantages such as technical limitations, expensive cost and poor patient comfort. In the present study, we aimed to investigate the efficacy and safety of Venous Infusion Chemotherapy（VIC） plus camrelizumab and apatinib for CNLC stage Ⅲ HCC. Method This study is a single-arm, open, prospective clinical study planned to enroll 35 untreated patients with stage CNLCⅢ hepatocellular carcinoma. Eligible pts received VIC （oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-fluorouracil bolus 400 mg/m² on day 1, and 5-fluorouracil infusion 2400 mg/m² for 46 hours; q3w; 6 cycles）, combined with apatinib （250 mg qd） and camrelizumab （200 mg q3w）. The primary study endpoints were objective response rate （ORR） assessed based on the RECIST 1.1 criteria, while the secondary study endpoints included： ORR assessed based on RECIST 1.1, mRECIST criteria, and disease control rate （DCR）, progression-free survival time （PFS）, overall survival time （OS）, surgical conversion rate, adverse reactions （AE）, etc. Results Data of 26 liver cancer patients who met the entry criteria and signed the consent form from April 2021 to April 2023 were collected and analyzed. The median follow-up was 13 months, ORR 61.5% （RECISTv1.1） and 73.1% （mRECIST）, cCR rate 26.9%, pCR 23.1%, DCR 96.2%, and mPFS and mOS were not reached, both over 9 months. The surgical conversion rate was 57.7%, all achieving R0 resection. The incidence of treatment-related adverse effects （TRAE） grade 3 AEs was 50%. Conclusion The triplet treatment of VIC plus camrelizumab and apatinib showed promising antitumor activity and acceptable safety for CNLC stage Ⅲ HCC,and the preliminary study effect is similar to that of FOLFOX-HAIC combined with camrelizumab and apatinib . Especially for patients with main portal vein cancer thrombus, the combined treatment scheme is worthy of clinical application.

Key words: hepatocellular carcinoma, main portal vein cancer thrombus, venous infusion chemotherapy, ICIs, AATDs

中图分类号:

R735.7

彭林辉, 陈涛, 徐云修修, 王捷, 陈捷, 李永, 黄拼搏, 钟国平, 陈茜, 叶聪婷, 陈亚进. mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼治疗CNLC Ⅲ期肝细胞癌有效性和安全性的前瞻性研究[J]. 岭南现代临床外科, 2024, 24(01): 1-6.

PENG Lin-hui, CHEN Tao, XU Yun-xiu-xiu, WANG Jie, CHEN Jie, LI Yong, HUANG Pin-bo, ZHONG Guo-ping, CHEN Qian, YE Cong-ting, CHEN Ya-jin. mFOLFOX7 venous chemotherapy plus camrelizumab and apatinib for hepatocellular carcinoma in CNLC stage Ⅲ （VIC-TRIPLET）： a prospective study[J]. Lingnan Modern Clinics In Surgery, 2024, 24(01): 1-6.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3] 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J]. 中华肝胆外科杂志, 2021, 27(4): 241-241.
[4] Cheng AL, Kang YK, Chen ZD, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[5] Cheng AL, Kang YK, Chen Z, et al.Efficacy and safety of sorafenibin patients in the Asia-Pacific region with advan- ced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[6] Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus bevaci-zumabin unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[7] Qin S, Ren Z, Feng YH, et al: Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study[J]. Liver cancer, 2021, 10(4): 296-308.
[8] Galle PR, Finn RS, Qin S, et al: Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001.
[9] 樊嘉, 高强. 肝癌的免疫治疗:有希望便是光明[J]. 中华消化外科杂志, 2022, 21(2): 199-204.
[10] Shukui Qin. LBA35 - Camrelizumab (C) plus Rivoceranib (R) vs. Sorafenib (S) as First-Line Therapy for Unresectable Hepatocellular Carcinoma (UHCC): A Randomized, Phase Ⅲ Trial[C/OL]//ESMO Congress. Proffered Paper session 1: GI, upper digestive: Annals of Oncology(2022), 2022: S808-S869.[2022-09-13].
[11] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022,21(02) : 143-168.
[12] Xu J, Shen J, Gu S, et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma. (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[13] Xu J, Zhang Y, Jia R, et al.Anti-PD- 1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523.
[14] Lencioni R, Llovet JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60.
[15] SatoY, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602[J]. Ups J Med Sci, 2013, 118(1): 16-22.
[16] Shukui Qin, Yuxian Bai, Ho Yeong Lim, et al.Randomized, multicenter, open label study of oxaliplatin plus fluorouracil/ leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
[17] Qin YK, Cheng Y, Liang J, et al.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: A subgroup analysis of the EACH study[J]. Oncologist, 2014, 19(11): 1169-1178.
[18] Goyal L, Zheng H, Abrams TA, et al: A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma[J]. Clin Cancer Res, 2019, 25(1): 80-89.
[19] Ren Z, Xu J, Bai Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[20] Kudo M, Ikeda M, Motomura K, et al.A phase Ⅰb study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): study 117[J]. J Clin Oncol, 2020, 38(4_suppl): 513.
[21] Llovet JM, Kudo M,Merle P, et al.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(12): 1399-1410.
[22] Qin S, Chan SL, Gu S, et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146.
[23] Chung HC, Bang YJ, S Fuchs C, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021, 17(5): 491-501.
[24] Tiegs G, Lohse AW.Immune tolerance: what is unique about the liver[J]. J Autoimmun, 2010, 34(1): 1-6.
[25] 刘潇衍. 肿瘤化疗联合免疫治疗从理论基础到临床实践[J]. 中国肿瘤临床, 2017, 44(9): 452-458.
[26] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[27] Zhu H, Shan Y, Ge K, et al.Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy[J]. Cell Oncol (Dordr), 2020, 43(6): 1203-1214.
[28] Liu M, Shi J, Mou T, et al.Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol Hepatol, 2020, 35(8): 1277-1287.
[29] Lyu N, Kong Y, Mu L, et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69.
[30] Lyu N, Lin Y, Kong Y, et al.FOXAI: a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396.
[31] 陈敏山, 胡自力. 肝动脉灌注化疗在肝癌转化治疗中的研究进展[J]. 中华消化外科杂志, 2021, 20(2): 171-177.
[32] Yan JX, Deng MJ, Li T, et al.Efficacy and complications of transarterial chemoembolization alone or in combination with different protocols for hepatocellular carcinoma: A Bayesian network meta-analysis of randomized controlled trials[J]. iLIVER, 2023, 2(2): 130-141.
[33] He MK, Shi M, Lai ZC, et al.A phase Ⅱ trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study)[J]. J Clin Oncol, 2021, 39(15_suppl): 4083.
[34] 刘东明, 穆瀚, 刘长富, 等. 免疫及靶向药物联合肝动脉灌注化疗治疗晚期肝癌的回顾性分析[J]. 中国肿瘤临床, 2023, 50(17): 888-892.
[35] Zhang TQ, Zuo MX, Geng ZJ, et al.Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)[J]. Ann Oncol, 2021, 32(suppl 5): S825.
[36] 徐永康, 付舒敏, 李丹, 等. 肝动脉灌注化疗联合卡瑞利珠单抗和仑伐替尼治疗肝癌合并VP3/4型门静脉癌栓的近期疗效与安全性[J]. 南昌大学学报(医学版), 2022, 62(5): 32-37.
[37] Chen CT, Liu TH, Shao YY, et al.Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma[J]. Int J Mol Sci, 2021, 22(23).